Aerovate Therapeutics (AVTE) Expected to Announce Quarterly Earnings on Monday

Aerovate Therapeutics (NASDAQ:AVTE) will likely be announcing its earnings results before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter.

Aerovate Therapeutics Stock Performance

AVTE opened at $2.47 on Monday. The firm’s fifty day moving average is $2.50 and its two-hundred day moving average is $2.40. The firm has a market cap of $71.32 million, a PE ratio of -0.83 and a beta of 1.01. Aerovate Therapeutics has a twelve month low of $1.25 and a twelve month high of $32.42.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.